In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $0.61.
According to TipRanks, Pantginis is an analyst with an average return of -6.9% and a 32.49% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Celldex, Panbela Therapeutics, and Onconova Therapeutics.
Currently, the analyst consensus on Tempest Therapeutics is a Moderate Buy with an average price target of $21.50.
See Insiders’ Hot Stocks on TipRanks >>
Based on Tempest Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.64 million. In comparison, last year the company had a GAAP net loss of $8.49 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Millendo Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in the development of novel treatments for endocrine diseases. Its products include livoletide and nevanimibe. The company was founded in April, 2011 and is headquartered in Ann Arbor, MI.
Read More on TPST:
